HeimLSTA • NASDAQ
add
Lisata Therapeutics Inc
Við síðustu lokun
5,01 $
Dagbil
5,01 $ - 5,03 $
Árabil
1,81 $ - 5,06 $
Markaðsvirði
45,34 m. USD
Meðalmagn
72,69 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | des. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 100,00 þ. | -90,00% |
Rekstrarkostnaður | 3,18 m. | -46,56% |
Nettótekjur | -2,95 m. | 35,92% |
Hagnaðarhlutfall | -2,95 þ. | -540,78% |
Hagnaður á hvern hlut | — | — |
EBITDA | -3,06 m. | 37,57% |
Virkt skatthlutfall | 0,00% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | des. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 15,96 m. | -48,93% |
Heildareignir | 17,74 m. | -49,31% |
Heildarskuldir | 3,14 m. | -44,71% |
Eigið fé alls | 14,60 m. | — |
Útistandandi hlutabréf | 9,03 m. | — |
Eiginfjárgengi | 2,98 | — |
Arðsemi eigna | -38,97% | — |
Ávöxtun eigin fjár | -48,53% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | des. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | -2,95 m. | 35,92% |
Handbært fé frá rekstri | -3,25 m. | 28,25% |
Reiðufé frá fjárfestingum | 0,00 | -100,00% |
Reiðufé frá fjármögnun | 205,00 þ. | 313,54% |
Breyting á handbæru fé | -3,04 m. | 7,82% |
Frjálst peningaflæði | -2,35 m. | 20,28% |
Um
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Stofnsett
1980
Höfuðstöðvar
Vefsvæði
Starfsfólk
21
